Startup profile · funding coverage
Adaptyv funding, valuation and investors
YC S21 automated wet lab that synthesizes and tests AI-designed proteins and returns experimental data.
Keep track of Adaptyv
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$40M · August 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$48M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Lausanne, Switzerland (Biopôle / Épalinges)
Overview
Adaptyv Bio (Adaptyv Biosystems) is a Lausanne company building an automated protein foundry so researchers and AI agents can submit sequences and get wet-lab measurements back. Y Combinator lists it in the Summer 2021 batch. On August 25, 2026 it announced a $40 million Series A led by Highland Europe; ACE Ventures, byFounders, and Y Combinator participated. The company post cites more than 5x lab throughput growth over the prior year and more than 100 customers, including bio-AI labs Chai Discovery and Boltz and pharmas Roche and Novo Nordisk. It also describes a collaboration in which Anthropic’s Claude designed proteins that were tested in Adaptyv’s lab. Valuation and revenue were not disclosed in that post. ACE Ventures led an $8 million seed dated September 25, 2025 on ACE’s own site. Highland Europe, ACE Ventures, and byFounders do not have Venture Capital Tracker /fund/ pages; Y Combinator does.
Why Adaptyv is interesting
August 25, 2026: $40M Series A led by Highland Europe with YC, ACE Ventures, and byFounders returning. No valuation. Company names Chai Discovery, Boltz, Roche, and Novo Nordisk among 100+ customers and says lab throughput grew more than 5x in a year.
Product & use cases
Automated wet lab and API for synthesizing and testing designed proteins, so AI design loops can close against physical measurements rather than in-silico scores alone.
- AI biology labs validating designed binders
- Pharma groups that want faster binding measurements than an in-house 20-designs-per-target lab
- Agent-submitted experiments via API (company)
Key facts
- Aug 25, 2026: $40M Series A; Highland Europe lead; YC / ACE / byFounders returning; no valuation
- YC Summer 2021; Lausanne automated protein lab
- Company: >5x throughput; >100 customers; names Chai Discovery, Boltz, Roche, Novo Nordisk
- Prior: $8M seed led by ACE Ventures (ACE post Sep 25, 2025)
- No /fund/ pages for Highland Europe, ACE Ventures, or byFounders
Funding history (newest first)
Series A
2026-08 $40M- Highland Europe (lead)
- Y Combinator (participant)
- ACE Ventures (participant)
- byFounders (participant)
Seed
2025-09 $8M- ACE Ventures (lead)
- byFounders (participant)
Investors in our directory
Funds linked from Adaptyv's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: A disclosed Series A that prices lab capacity, not a therapeutic asset — plus named model-lab and pharma customers on the company post. That is an infrastructure signal, not a drug.
Adaptyv is a Series A bet that AI protein design is already faster than most wet labs, so the scarce asset is copyable automated workcells. Diligence is utilization and contract quality — not a valuation, which was not disclosed.
-
Chai Discovery adjacent
Customer on Adaptyv’s Series A post. Chai sells molecular-design models ($400M Series C at $3.8B, July 2026). See /2026-chai-discovery-400m-series-c-index-sequoia.
-
Boltz adjacent
Customer on Adaptyv’s Series A post. MIT-origin protein AI PBC. See /startup/boltz.
-
AusperBio adjacent
Same-month nine-figure therapeutics print ($120M Series C). Drug company, not a lab. See /startup/ausperbio.
Notable stories
- The August 25, 2026 company post names Chai Discovery and Boltz as customers. Those are company-named logos, not disclosed contract values.
- ACE Ventures dates the $8M seed to September 25, 2025. Some August 2026 recaps say late 2024 — do not overwrite ACE’s date without a company correction.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Adaptyv's financing or category context.
FAQs about Adaptyv
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.